A Novel Initiative to Treat and Cure ALS
We are laying the foundation for game-changing participation by the world's leading pharmaceutical and medical research companies; in doing so, we are taking significant steps toward treatment—and a cure—for ALS About Us »
THE FUTURE » TARGET ALS PROVIDES AN ORGANIZATIONAL FRAMEWORK FOR THE WORLD'S LEADING ALS RESEARCHERS TO SHARE AND COORDINATE THEIR FINDINGS, SO THAT WE CAN MAKE PROGRESS TOWARD THERAPIES AND A CURE. —Dan Doctoroff

Resources available from Target ALS for academia and industry: Investigators retain ownership of data and intellectual property generated from use of Target ALS resources

NEW RESOURCE:Target ALS has generated thepoly(GP)monoclonal antibodyfrom two hybridoma clones and is making themavailable to the ALS research community worldwide.Investigators interested in the moreimmunoreactive of thetwo purifiedpoly(GP)monoclonalantibodies (TALS 828.179) can contact Target ALS at manish.raisinghani@targetals.org. Additionally, the two hybridoma clones have been deposited at the Developmental Studies Hybridoma Bank (DHSB). The supernatant from both clones (TALS 828.179 and TALS 828.66) work similarly in validation assays and can be accessed by contacting DHSB directly at http://dshb.biology.uiowa.edu.Additional resources to support the study ofC9orf72 ALScomingonline soon!

Human postmortem tissue: Multiple CNS sub-regions from ALS and control cases with detailed de-identified clinical and demographic information

(explore Target ALS human postmortem tissue inventory)

Whole genome sequenced dataset of post-mortem tissue samples.

The samples are being RNA sequenced. To access the RNAseq data, please contact alsdata@nygenome.org

Human stem cell lines: Well-characterized iPSC lines from ALS and control cases with detailed de-identified clinical and demographic information

(search and order from Target ALS stem cell inventory)